Wedbush Issues Positive Forecast for First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Price

First Tracks Biotherapeutics (NASDAQ:TRAX) had its price target boosted by equities research analysts at Wedbush from $30.00 to $60.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 42.76% from the stock’s previous close.

TRAX has been the topic of a number of other research reports. Wells Fargo & Company restated an “overweight” rating and set a $55.00 price target (up from $30.00) on shares of First Tracks Biotherapeutics in a research note on Tuesday. UBS Group assumed coverage on First Tracks Biotherapeutics in a research note on Tuesday, April 21st. They issued a “buy” rating and a $45.00 price objective for the company. Piper Sandler assumed coverage on First Tracks Biotherapeutics in a report on Monday, May 4th. They issued an “overweight” rating and a $54.00 price objective for the company. Wall Street Zen upgraded shares of First Tracks Biotherapeutics to a “hold” rating in a research note on Saturday, May 2nd. Finally, JPMorgan Chase & Co. began coverage on shares of First Tracks Biotherapeutics in a research report on Thursday, April 23rd. They set an “overweight” rating and a $31.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $47.88.

First Tracks Biotherapeutics Trading Up 18.3%

Shares of TRAX opened at $42.03 on Tuesday. First Tracks Biotherapeutics has a 1-year low of $14.72 and a 1-year high of $46.45. The stock has a market capitalization of $1.47 billion and a PE ratio of -22.84. The company has a fifty day moving average of $22.37.